JP7068825B2 - Ｃｄ３８に結合する抗体治療剤 - Google Patents

Ｃｄ３８に結合する抗体治療剤 Download PDF

Info

Publication number
JP7068825B2
JP7068825B2 JP2017552973A JP2017552973A JP7068825B2 JP 7068825 B2 JP7068825 B2 JP 7068825B2 JP 2017552973 A JP2017552973 A JP 2017552973A JP 2017552973 A JP2017552973 A JP 2017552973A JP 7068825 B2 JP7068825 B2 JP 7068825B2
Authority
JP
Japan
Prior art keywords
seq
antibody
chain variable
variable domain
antigen
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
JP2017552973A
Other languages
English (en)
Japanese (ja)
Other versions
JP2018513149A (ja
JP2018513149A5 (enExample
Inventor
ヘユー・ジョウ
ジョン・ディクソン・グレイ
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sorrento Therapeutics Inc
Original Assignee
Sorrento Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sorrento Therapeutics Inc filed Critical Sorrento Therapeutics Inc
Publication of JP2018513149A publication Critical patent/JP2018513149A/ja
Publication of JP2018513149A5 publication Critical patent/JP2018513149A5/ja
Priority to JP2021086783A priority Critical patent/JP7273101B2/ja
Application granted granted Critical
Publication of JP7068825B2 publication Critical patent/JP7068825B2/ja
Priority to JP2022101169A priority patent/JP2022118222A/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/72—Increased effector function due to an Fc-modification
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2800/00—Nucleic acids vectors

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Oncology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Cell Biology (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
JP2017552973A 2015-04-08 2016-04-08 Ｃｄ３８に結合する抗体治療剤 Expired - Fee Related JP7068825B2 (ja)

Priority Applications (2)

Application Number Priority Date Filing Date Title
JP2021086783A JP7273101B2 (ja) 2015-04-08 2021-05-24 Ｃｄ３８に結合する抗体治療剤
JP2022101169A JP2022118222A (ja) 2015-04-08 2022-06-23 Ｃｄ３８に結合する抗体治療剤

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562144901P 2015-04-08 2015-04-08
US62/144,901 2015-04-08
PCT/US2016/026567 WO2016164669A2 (en) 2015-04-08 2016-04-08 Antibody therapeutics that bind cd38

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2021086783A Division JP7273101B2 (ja) 2015-04-08 2021-05-24 Ｃｄ３８に結合する抗体治療剤

Publications (3)

Publication Number Publication Date
JP2018513149A JP2018513149A (ja) 2018-05-24
JP2018513149A5 JP2018513149A5 (enExample) 2019-05-16
JP7068825B2 true JP7068825B2 (ja) 2022-05-17

Family

ID=57072959

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2017552973A Expired - Fee Related JP7068825B2 (ja) 2015-04-08 2016-04-08 Ｃｄ３８に結合する抗体治療剤
JP2021086783A Active JP7273101B2 (ja) 2015-04-08 2021-05-24 Ｃｄ３８に結合する抗体治療剤
JP2022101169A Pending JP2022118222A (ja) 2015-04-08 2022-06-23 Ｃｄ３８に結合する抗体治療剤

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2021086783A Active JP7273101B2 (ja) 2015-04-08 2021-05-24 Ｃｄ３８に結合する抗体治療剤
JP2022101169A Pending JP2022118222A (ja) 2015-04-08 2022-06-23 Ｃｄ３８に結合する抗体治療剤

Country Status (8)

Country Link
US (4) US10059774B2 (enExample)
EP (2) EP3280443B1 (enExample)
JP (3) JP7068825B2 (enExample)
CN (2) CN113527495A (enExample)
AR (1) AR104213A1 (enExample)
ES (1) ES2927119T3 (enExample)
TW (1) TW201702264A (enExample)
WO (2) WO2016164656A1 (enExample)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN113527495A (zh) 2015-04-08 2021-10-22 索伦托药业有限公司 与cd38结合的抗体治疗剂
US10100118B2 (en) 2015-04-08 2018-10-16 Sorrento Therapeutics, Inc. Antibody therapeutics that bind CD123
AU2018273914A1 (en) 2017-05-24 2019-11-14 Pandion Operations, Inc. Targeted immunotolerance
JP7234142B2 (ja) 2017-06-02 2023-03-07 ファイザー・インク Ｆｌｔ３に特異的な抗体およびその使用
US11780930B2 (en) 2017-06-08 2023-10-10 Black Belt Therapeutics Limited CD38 modulating antibody
KR102770106B1 (ko) 2017-06-08 2025-02-21 블랙 벨트 테라퓨틱스 리미티드 Cd38 조정 항체
JP7359700B2 (ja) * 2017-06-20 2023-10-11 ソレント・セラピューティクス・インコーポレイテッド Ｃｄ３８抗体薬物コンジュゲート
JP7299873B2 (ja) * 2017-08-16 2023-06-28 ブラック ベルト セラピューティクス リミテッド Ｃｄ３８抗体
AU2018316521B2 (en) 2017-08-16 2025-01-30 Black Belt Therapeutics Limited CD38 modulating antibody
US11542338B2 (en) 2017-08-16 2023-01-03 Black Belt Therapeutics Limited CD38 modulating antibody
WO2019035938A1 (en) 2017-08-16 2019-02-21 Elstar Therapeutics, Inc. MULTISPECIFIC MOLECULES BINDING TO BCMA AND USES THEREOF
KR20200076732A (ko) 2017-11-03 2020-06-29 소렌토 쎄라퓨틱스, 인코포레이티드 Cd38-지시된 키메라 항원 수용체 작제물
US10946068B2 (en) 2017-12-06 2021-03-16 Pandion Operations, Inc. IL-2 muteins and uses thereof
US10174091B1 (en) 2017-12-06 2019-01-08 Pandion Therapeutics, Inc. IL-2 muteins
SG11202008568WA (en) 2018-03-09 2020-10-29 Sorrento Therapeutics Inc Dimeric antigen receptors (dar)
JP7637510B2 (ja) * 2018-06-20 2025-02-28 ビバソル， インコーポレイテッド Ｃｄ３８に結合するバリアント抗体
CN112513087B (zh) 2018-09-11 2023-01-24 江苏恒瑞医药股份有限公司 抗cd38抗体、其抗原结合片段及医药用途
JP7555953B2 (ja) * 2019-03-29 2024-09-25 ソレント・セラピューティクス・インコーポレイテッド Ｃｄ３８に結合する操作されたバリアント抗体
AU2020279240A1 (en) 2019-05-20 2021-12-23 Pandion Operations, Inc. MAdCAM targeted immunotolerance
AU2020299774A1 (en) * 2019-07-03 2022-01-20 Peptidream Inc. CD38-binding agents and uses thereof
CN114728179A (zh) * 2019-08-19 2022-07-08 潘迪恩运营公司 利用pd-1激动剂的靶向免疫耐受
WO2021113596A2 (en) 2019-12-05 2021-06-10 Sorrento Therapeutics, Inc. Compositions and methods comprising an anti-cd47 antibody in combination with a tumor targeting antibody
US11981715B2 (en) 2020-02-21 2024-05-14 Pandion Operations, Inc. Tissue targeted immunotolerance with a CD39 effector
WO2021168192A2 (en) * 2020-02-21 2021-08-26 Pandion Operations, Inc. Tissue targeted immunotolerance with pd-1 agonists or il-2 muteins
WO2022015956A1 (en) 2020-07-15 2022-01-20 Sorrento Therapeutics, Inc. Improved process for dna integration using rna-guided endonucleases
JP2023538367A (ja) * 2020-08-19 2023-09-07 パンディオン・オペレーションズ・インコーポレイテッド マルチパラトピック抗ｐｄ－１抗体およびその用途
US12181485B2 (en) * 2020-09-10 2024-12-31 CASI Pharmaceuticals, Inc Methods of blood screening

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20130171154A1 (en) 2010-12-30 2013-07-04 Takeda Pharmaceutical Company Limited Anti-cd38 antibodies

Family Cites Families (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL154598B (nl) 1970-11-10 1977-09-15 Organon Nv Werkwijze voor het aantonen en bepalen van laagmoleculire verbindingen en van eiwitten die deze verbindingen specifiek kunnen binden, alsmede testverpakking.
US3901654A (en) 1971-06-21 1975-08-26 Biological Developments Receptor assays of biologically active compounds employing biologically specific receptors
US3817827A (en) 1972-03-30 1974-06-18 Scott Paper Co Soft absorbent fibrous webs containing elastomeric bonding material and formed by creping and embossing
US4179337A (en) 1973-07-20 1979-12-18 Davis Frank F Non-immunogenic polypeptides
US4098876A (en) 1976-10-26 1978-07-04 Corning Glass Works Reverse sandwich immunoassay
JPS6023084B2 (ja) 1979-07-11 1985-06-05 味の素株式会社 代用血液
US4640835A (en) 1981-10-30 1987-02-03 Nippon Chemiphar Company, Ltd. Plasminogen activator derivatives
US4496689A (en) 1983-12-27 1985-01-29 Miles Laboratories, Inc. Covalently attached complex of alpha-1-proteinase inhibitor with a water soluble polymer
EP0206448B1 (en) 1985-06-19 1990-11-14 Ajinomoto Co., Inc. Hemoglobin combined with a poly(alkylene oxide)
US4791192A (en) 1986-06-26 1988-12-13 Takeda Chemical Industries, Ltd. Chemically modified protein with polyethyleneglycol
US4946778A (en) 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
US6010902A (en) 1988-04-04 2000-01-04 Bristol-Meyers Squibb Company Antibody heteroconjugates and bispecific antibodies for use in regulation of lymphocyte activity
GB9014932D0 (en) 1990-07-05 1990-08-22 Celltech Ltd Recombinant dna product and method
JP3051145B2 (ja) 1990-08-28 2000-06-12 住友製薬株式会社 新規なポリエチレングリコール誘導体修飾ペプチド
US5582996A (en) 1990-12-04 1996-12-10 The Wistar Institute Of Anatomy & Biology Bifunctional antibodies and method of preparing same
DE4118120A1 (de) 1991-06-03 1992-12-10 Behringwerke Ag Tetravalente bispezifische rezeptoren, ihre herstellung und verwendung
WO1994004679A1 (en) 1991-06-14 1994-03-03 Genentech, Inc. Method for making humanized antibodies
JPH05244982A (ja) 1991-12-06 1993-09-24 Sumitomo Chem Co Ltd 擬人化ｂ−ｂ１０
PT672141E (pt) 1992-10-23 2003-09-30 Immunex Corp Metodos de preparacao de proteinas oligomericas soluveis
US5932462A (en) 1995-01-10 1999-08-03 Shearwater Polymers, Inc. Multiarmed, monofunctional, polymer for coupling to molecules and surfaces
US5731168A (en) 1995-03-01 1998-03-24 Genentech, Inc. Method for making heteromultimeric polypeptides
GB9722131D0 (en) 1997-10-20 1997-12-17 Medical Res Council Method
JP2002522063A (ja) 1998-08-17 2002-07-23 アブジェニックス インコーポレイテッド 増加した血清半減期を有する改変された分子の生成
GB9928787D0 (en) 1999-12-03 2000-02-02 Medical Res Council Direct screening method
AU2001268427B2 (en) 2000-06-16 2007-03-29 Glaxosmithkline Intellectual Property Limited Antibodies that immunospecifically bind to blys
US6938003B2 (en) 2000-06-30 2005-08-30 Mahesh Harpale Method and apparatus for a credibility reporting system to augment an online exchange
GB0025144D0 (en) 2000-10-13 2000-11-29 Medical Res Council Concatenated nucleic acid sequences
IL159177A0 (en) * 2001-06-20 2004-06-01 Prochon Biotech Ltd Antibodies that block receptor protein tyrosine kinase activation, methods of screening for and uses thereof
US20040202995A1 (en) 2003-04-09 2004-10-14 Domantis Nucleic acids, proteins, and screening methods
CN1976950B (zh) * 2004-02-06 2012-08-29 莫佛塞斯公司 抗cd38人抗体及其用途
EP2915820A1 (en) 2004-02-06 2015-09-09 MorphoSys AG Anti-CD38 human antibodies and uses therefor
EP2551282A3 (en) 2005-03-23 2013-02-13 Genmab A/S Antibodies against CD38 for treatment of multiple myeloma
CN101287764B (zh) * 2005-10-12 2013-11-13 莫佛塞斯公司 特异性针对人CD38的完全人HuCAL GOLD-衍生治疗抗体的生成和鉴定
US9221902B2 (en) * 2008-11-07 2015-12-29 Fabrus, Inc. Combinatorial antibody libraries and uses thereof
WO2010141249A2 (en) 2009-06-02 2010-12-09 Merck Sharp & Dohme Corp. Generation, characterization and uses thereof of anti-notch3 antibodies
EP2580243B1 (en) * 2010-06-09 2019-10-16 Genmab A/S Antibodies against human cd38
US8877899B2 (en) * 2010-09-27 2014-11-04 Morphosys Ag Anti-CD38 antibody and lenalidomide or bortezomib for the treatment of multipe myeloma and NHL
US9120858B2 (en) * 2011-07-22 2015-09-01 The Research Foundation Of State University Of New York Antibodies to the B12-transcobalamin receptor
EP3021866A4 (en) * 2013-07-15 2017-02-22 The Board of Trustees of the Leland Stanford Junior University Medical uses of cd38 agonists
CN113527495A (zh) 2015-04-08 2021-10-22 索伦托药业有限公司 与cd38结合的抗体治疗剂

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20130171154A1 (en) 2010-12-30 2013-07-04 Takeda Pharmaceutical Company Limited Anti-cd38 antibodies

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
Ｃｌｉｎ．Ｃａｎｃｅｒ Ｒｅｓ．，２０１４年，Ｖｏｌ．２０，Ｎｏ．１７，ｐ．４５７４－４５８３

Also Published As

Publication number Publication date
US20190048092A1 (en) 2019-02-14
WO2016164656A1 (en) 2016-10-13
EP3280443A4 (en) 2018-12-26
JP7273101B2 (ja) 2023-05-12
EP3280443A2 (en) 2018-02-14
CN107921122A (zh) 2018-04-17
JP2018513149A (ja) 2018-05-24
JP2021118754A (ja) 2021-08-12
TW201702264A (zh) 2017-01-16
JP2022118222A (ja) 2022-08-12
HK1253584A1 (zh) 2019-06-21
AR104213A1 (es) 2017-07-05
EP4180058A1 (en) 2023-05-17
US11999792B2 (en) 2024-06-04
US20160297888A1 (en) 2016-10-13
US10800852B2 (en) 2020-10-13
CN107921122B (zh) 2021-08-10
US20170291959A1 (en) 2017-10-12
EP3280443B1 (en) 2022-08-24
WO2016164669A3 (en) 2017-01-12
ES2927119T3 (es) 2022-11-02
US20200399395A1 (en) 2020-12-24
CN113527495A (zh) 2021-10-22
US9951144B2 (en) 2018-04-24
WO2016164669A2 (en) 2016-10-13
US10059774B2 (en) 2018-08-28

Similar Documents

Publication Publication Date Title
JP7273101B2 (ja) Ｃｄ３８に結合する抗体治療剤
US10927171B2 (en) Antibody therapeutics that bind TIM3
KR102625835B1 (ko) Cd47에 결합하는 항체 치료제
US11746156B2 (en) Antibody therapeutics that bind CD123
US9969807B2 (en) Antibody therapeutics that bind CD123
HK40060959A (en) Antibody therapeutics that bind cd38
HK1253584B (en) Antibody therapeutics that bind cd38

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20190405

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20190405

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20200602

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20200901

RD03 Notification of appointment of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7423

Effective date: 20201112

RD04 Notification of resignation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7424

Effective date: 20201116

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20210126

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20210524

C60 Trial request (containing other claim documents, opposition documents)

Free format text: JAPANESE INTERMEDIATE CODE: C60

Effective date: 20210524

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20210601

C21 Notice of transfer of a case for reconsideration by examiners before appeal proceedings

Free format text: JAPANESE INTERMEDIATE CODE: C21

Effective date: 20210602

A912 Re-examination (zenchi) completed and case transferred to appeal board

Free format text: JAPANESE INTERMEDIATE CODE: A912

Effective date: 20210702

C211 Notice of termination of reconsideration by examiners before appeal proceedings

Free format text: JAPANESE INTERMEDIATE CODE: C211

Effective date: 20210706

C22 Notice of designation (change) of administrative judge

Free format text: JAPANESE INTERMEDIATE CODE: C22

Effective date: 20220201

C23 Notice of termination of proceedings

Free format text: JAPANESE INTERMEDIATE CODE: C23

Effective date: 20220311

C03 Trial/appeal decision taken

Free format text: JAPANESE INTERMEDIATE CODE: C03

Effective date: 20220407

C30A Notification sent

Free format text: JAPANESE INTERMEDIATE CODE: C3012

Effective date: 20220407

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20220502

R150 Certificate of patent or registration of utility model

Ref document number: 7068825

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

S111 Request for change of ownership or part of ownership

Free format text: JAPANESE INTERMEDIATE CODE: R313113

S531 Written request for registration of change of domicile

Free format text: JAPANESE INTERMEDIATE CODE: R313531

R350 Written notification of registration of transfer

Free format text: JAPANESE INTERMEDIATE CODE: R350

LAPS Cancellation because of no payment of annual fees